A phase I dose-escalation clinical trial of SB-509-0401 [SB 509] in subjects with diabetic neuropathy
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2017
At a glance
- Drugs SB 509 (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions
- 03 Dec 2008 Full data set presented at a Sangamo BioSciences Investor and Analyst briefing
- 15 Sep 2008 Positive 180-day results presented at the 44th EASD, according to a Sangamo media release.
- 06 Jun 2008 Status changed from recruiting to completed according to Sangamo BioSciences.